EVEREST MED.LTD DL-0001 risk profile
43 Elevated one input has moved against it
Measured 10 September 2026 from 6HN's filed statements. Recomputed nightly.
43 (Elevated), driven by Cash conversion at 100, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 85 | Acute | Worsening | Drawdown from the 52-week high — 49.6% |
| Operating pressure | 0 | Contained | Stable | Costs outgrowing revenue — -98.3 percentage points |
| Cash conversion | 100 | Acute | Stable | Capital spending against operating cash — -3.76x |
| Leverage and coverage | 35 | Normal | Easing | Interest cover — -17.99x |
| Competitive position | 46 | Elevated | Stable | Operating-margin gap against peers — -17.3 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 34Johnson & Johnson 39Abbvie Inc 58Roche Holding AG 36Merck & Co Inc 35Unitedhealth Group Inc 49Novartis AG 30Astrazeneca plc 33Thermo Fisher Scientific Inc 47AMGEN Inc 47Novo Nordisk A/S 23Abbott Laboratories 37
Financials, valuation and price history for EVEREST MED.LTD DL-0001